natgillin/translations-raw huggingface dataset:
In an especially preferred embodiment, the hydrophobizing agent is selected from the group comprising fatty acids, such as stearic acid, palmitic acid, and their salts; alkylketene dimer; polyacrylamide resins; silicone resins, polysiloxanes, preferably polysiloxane modified with functional silicone resin, and mixtures thereof. 
Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da sredstvo za hidrofobiziranje se bira iz skupine koju čine masne kiseline, kao što su stearinska kiselina, palmitinska kiselina, te njihove soli; alkilketenski dimer; poliakrilamidne smole; silikonske smole, polisiloksani, poželjno polisiloksan izmijenjen s funkcionalnom silikonskom smolom, te njihove smjese.
The method of item 30 further comprising a sequential dose of 1 mg/kg in the escalating dose regimen. 
KSM za uporabu u skladu s patentnim zahtjevom 10 ili 11, pri čemu nadalje metoda sadrži sekvencijalnu dozu od 1 mg/kg rhKSM u režimu povećavanja doze.
Mineralizers are substances that act as fluxing agent and/or lower the temperature required to form a melt and/or that promote the formation of the clinker compound, for example by the formation of solid solution crystals and/or phase stabilization. 
Vezivno sredstvo sukladno zahtjevu 1 ili 2, naznačeno time što su prisutni prirodni i/ili smtetički latentni hidraulički materijali i/ili pucolanski materijali, pri čemu količine vezivnih sredstava od ternesit i portland cementa imaju opseg u odnosu na količinu takvih dodataka i/ili mješavina:
A swallowable tablet comprising at least 80% by weight of N-acetylcysteine and at least one pharmaceutically acceptable excipient selected from the group comprising binders, diluents, disintegrating agents, lubricants and glidants, characterized in that the said tablet is manufactured using a granulate prepared by a process of the dry granulation of N-acetylcysteine alone, and wherein said tablet comprises a granulate of N-acetylcysteine alone, at least one binder in a quantity of 5% or more, at least one diluent in a quantity of 5% or more, at least one disintegrating agent in a quantity of 5% or more, at least one lubricant in a quantity of 1% or less, at least one glidant in a quantity of 1% or less, by weight with respect to the total weight of the tablet. 
Tableta za gutanje koja obuhvaća N-acetilcistein od najmanje 80% po masi i najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo odabrano iz skupine koju čine veziva, razrjeđivači, dezintegratori, maziva 1 klizna sredstva, naznačena time, da se navedena tableta proizvodi uporabom granulata pripravljenog putem postupka suhe granulacije samog N-acetilcisteina, te time, da navedena tableta obuhvaća granulat od samog N-acetilcisteina, najmanje jedno vezivo u količini od 5% ili više, najmanje jedan razrjeđivač u količini od 5% ili više, najmanje jedan dezintegrator u količini od 5% ili više, najmanje jedno mazivo u količini od 1% 1li manje, najmanje jedno klizno sredstvo u količini od 1% ili manje, po masi u odnosu na ukupnu masu tablete.
A solid composition according to claim 1, comprising cocoa butter in an amount of from about 5% to about 94% by weight of the total composition. A solid composition according to claim 6, comprising cocoa butter in an amount of from about 60% to about 80% by weight of the total composition. 
Ne-jestivi kruti kozmetički pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time da sadrži kakao maslac u količini od 5% do 94 masenih% ukupnog pripravka, poželjno u količini od 60% do 80 masenih% ukupnog pripravka.
optionally, progressively decreasing the concentration of animal serum in the culture medium so as to obtain a total withdrawal of animal serum after several passages; and, obtaining adherent duck cell lines derived from ES cells, named duck EBx®, capable of proliferating in a basal medium in the absence of growth factors, feeder layer optionally without animal serum, and wherein said continuous diploid avian cell lines do not produce replication-competent endogenous retrovirus particles; 
€) progresivno snižavanje koncentracije hranjivih stanica u mediju kulture tako da se dobije potpuno uklanjanje hranjivog sloja nakon nekoliko pasaža, i daljnji uzgoj kulture stanica; f) dobivanje adherentnih kontinuiranih diploidnih ptičjih staničnih linija iz ES stanica koje su sposobne proliferirati u bazalnom mediju bez prisutnosti faktora rasta i hranjivog sloja, i gdje te ptičje stanične linije ne proizvode za replikaciju kompetentne endogene čestice retrovirusa.
The vaccine kit of claim 8 wherein the first container further comprises hepatitis B surface antigen, optionally adsorbed on aluminium phosphate. 
Cjepivni komplet u skladu s patentnim zahtjevom 23, naznačen time što prvi spremnik dodatno sadrži površinski antigen virusa hepatitisa B, adsorbiran na aluminijev fosfat.
The pharmaceutical agent of claim 14, which is an agent for the prophylaxis or treatment of hypogonadism, male climacteric disorder, frailty, cachexia or osteoporosis. 
Farmaceutsko sredstvo prema zahtjevu 14, naznačeno time, da je to sredstvo za profilaksu ili liječenje hipogonadizma, poremećaja muškog klimakterija, nemoći, kaheksije ili osteoporoze.
The antibody of claim 7, wherein the antibody comprises two heavy chains having the amino acid sequence of SEQ ID NO: 1 and two light chains having the amino acid sequence of SEQ ID NO: 3. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što protutijelo sadrži dva teška lanca s aminokiselinskim slijedom SEQ ID NO: 1 i dva laka lanca s aminokiselinskim slijedom SEQ ID NO: 3.
Melanoidins are relatively large molecules that can suitably be removed after completion of the caramelisation reaction by means of filtration or another separation technique that enables separation on the basis of molecular weight, size, hydrophobicity or charge. 
Melanoidini su relativno velike molekule koje se prikladno mogu ukloniti nakon dovršenja reakcije karamelizacije filtracijom ili drugim tehnikom odvajanja koja omogućuje odvajanje na temelju molekulske mase, veličine, hidrofobnosti ili naboja.
A pharmaceutical composition according to any one of claims 1 to 4, wherein said meglumine is: free meglumine or a pharmaceutically acceptable salt of meglumine. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da spomenuti arginin je slobodni L-arginin ili farmaceutski prihvatljiva sol od L-arginina.
Yield: 46% (overall) 
Iskorištenje: 46% (ukupno)
administration from the rat or the dog, respectively. 
administraciju iz štakora odnosno psa.
adding a base to at least a part of said phosphorus depleted feed solution to obtain a neutral or alkaline pH, causing aluminium hydroxide to precipitate; 
dodavanje (290) baze u barem dio spomenute otopine za raspršivanje osiromašene od fosfora kako bi se dobio neutralni ili alkalni pH, čime se uzrokuje taloženje aluminij hidroksida;
preparing a solution of a suitable base in a suitable organic solvent; 
R N H (D u prikladnom organskom otapalu;
Most preferred nitrogen protecting groups are acetyl, benzyl, benzyloxycarbonyl (Cbz), triethylsilyl (TES), trimethylsilyethoxymethyl (SEM), t-butoxycarbonyl (BOC), pyrrolidinylmethyl and pivaloyl. 
Spoj prema zahtjevu 1 ili 2, naznačen time, da R1 je dušikova zaštitna skupina odabrana od sljedećih: pivaloji, pirolidinilmetil, t-butoksikarbonil, benzil, trietilsilil, acetil, benziloksikarbonil (Cbz) i trimetilsilietoksimetil (SEM).
The process of claim 1, wherein the iron (III) complex with N-acetyl-L-aspartylated casein obtained in step (c) is clarified before being sent on for desiccation or spray-drying or freeze-drying. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se kompleks željeza(IIl) s N-acetil-L-aspartiliranim kazeinom dobiven u koraku (c) izbistri prije slanja na sušenje ili sušenje raspršivanjem ili sušenje smrzavanjem.
The use of a compound according to any one of claims 1 -8 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders. 
Uporaba spoja prema bilo kojem od patentnih zahtjeva od 1 do 8, naznačena time, da je za pripravu lijekova za terapeutsko i/ili profilaktičko liječenje depresije, poremećaja anksioznosti, bipolarnog poremećaja, hiperaktivnog poremećaja manjka pozornosti (ADHD), poremećaja uzrokovanih stresom, psihotičnih poremećaja, shizofrenije, neuroloških bolesti, Parkinsonove bolesti, neurodegenerativnih poremećaja, Alzheimerove bolesti, epilepsije, migrene, hipertenzije, zlouporabe droga, metaboličkih poremećaja, poremećaja hranjenja, dijabetesa, dijabetičkih komplikacija, pretilosti, dislipidemije, poremećaja potrošnje energije 1 asimilacije, poremećaja 1 oštećenja homeostaze tjelesne temperature, poremećaja spavanja 1 cirkadijalnog ritma te kardiovaskularnih poremećaja.
Still a further aspect of the present invention is a method for the treatment of a patient suffering from signs and symptoms of an underlying rheumatic disease and/or osteoarthritis, which comprises administering to said patient an effective amount of a glucocorticoid contained in a delayed-release dosage form, wherein said treatment is administered once daily for at least about two weeks. 
HR P20130148 T1 PATENTNI ZAHTJEVI Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu u liječenju bolesnika koji pate od znakova i simptoma bolesti koja ima reumatsku podlugu i/ili osteoartritisa, pri čemu se navedeno liječenje provodi davanjem lijeka jednom dnevno kroz najmanje dva tjedna.
Progesterone according to claim 1 or 2, wherein the treatment achieves a final progesterone serum level of not more than about 950 ng/ml. 
Progesteron u skladu s patentnim zahtjevom 1 ili 2, naznačen time što se liječenjem postiže konačna razina progesterona u serumu od najviše otprilike 9,50 ng/ml.
The method of claim 9, wherein the antigen presenting cell is a dendritic cell or a macrophage. 
Stanica domaćih u skladu s patentnim zahtjevom 6, pri čemu je stanica domaćin dendritička stanica ili stanica koja prezentira antigen.
Disclosed is the use of a compound of the present invention, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, for the preparation of a medicament for treating an HIV infection. 
. Farmaceutski sastav prema patentnom zahtjevu 1 pri čemu spoj formule IIB je spoj formule IIC: ili njegova farmaceutski prihvatljiva sol, solvat, stereoizomer i/ili ester, pri čemu:
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: [wherein R1 represents OR, NRR' which may form a ring or SR, in which R and R' independently represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms optionally substituted with one or a plurality of alkoxy groups having 1 to 8 carbon atoms, halogen atoms or hydroxyl groups, an aryl group optionally substituted with one or a plurality of alkyl groups having 1 to 8 carbon atoms, alkoxy groups having 1 to 8 carbon atoms or halogen atoms, or a heteroaryl group optionally substituted with one or a plurality of alkyl groups having 1 to 8 carbon atoms, an alkoxy groups having 1 to 8 carbon atoms or a halogen atom, R2 represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, and X1, X2 and X3 are independently CR3 or a nitrogen atom, or X1 is CR3 or a nitrogen atom, and X2 and X3 together form a benzene ring, in which R3 is a hydrogen atom or an alkyl group having 1 to 8 carbon atoms.] 
Spoj predstavljen formulom (I) ili njegova farmaceutski prihvatljiva sol: pri čemu R1 predstavlja OR, NRR' koji može tvoriti prsten ili SR, u kojem R i R' neovisno predstavljaju vodikov atom, ravnu, cikličku ili razgranatu alkilnu skupinu koja ima 1 do 8 ugljikovih atoma po izboru supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma, halogene atome ili hidroksilne skupine, arilnu skupinu proizvoljno supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkilnih skupina koje imaju 1 do 8 ugljikovih atoma, ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma ili halogene atome, ili heteroarilnu skupinu po izboru supstituiranu s jednom ili više ravnih, cikličkih ili razgranatih alkilnih skupina koje imaju 1 do 8 ugljikovih atoma, ravnih, cikličkih ili razgranatih alkoksi skupina koje imaju 1 do 8 ugljikovih atoma ili halogeni atom,
The pharmaceutical composition according to claim 1, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 12 h to 24 h following administration. 
Farmaceutski sastav za upotrebu prema patentnom zahtjevu 1, naznačen time da daje stacionarno stanje razina u plazmi 3 a-hidroksi-3fB-metoksimetil-2 1-(1*-imidazolil)-5a-pregnan-20-ona u rasponu od 5 ng/ml do 500 ng/ml u trajanju od 12 sati do 24 sata nakon davanja.
The method according to any one of the preceding claims, wherein the saturated temperature of the excess steam (7) and the saturated temperature of the compressed excess steam (8) differs by a temperature difference ATE, wherein ATE is from 6 to 130°C, preferably from 11 to 80°C, more preferably from 15 to 60°C, and most preferably from 20 to 45°C. 
Postupak u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da se zasićena temperatura viška pare (7) 1 zasićena temperatura komprimiranog viška pare (8) razlikuje temperaturnom razlikom ATg, pri čemu je ATg od 6 do 130"C, poželjno 11 do 80"C, poželjnije od 15 do 60"C i najpoželjnije od 20 do 45*C.
The compound of Formula 8 may be prepared by decarboxylating a compound of Formula 3, above, or a salt thereof, or by hydrolyzing and decarboxylating the compound of Formula 3 or a salt thereof, to yield the compound of Formula 8 or a salt thereof. 
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u redukciji cijano ostatka u spoju Formule 3 ili njegovoj soli, kako bi se dobilo spoj Formule 2, ili njegovu sol, gdje 25
A compound according to formula (I) wherein, 
Spoj prema zahtjevu 1, pri čemu je L2 veza.
the light conduction device is a flexible fiber-optic bundle and the convex lens of the bottom layer is coupled to the fiber-optic bundle; or the light conduction device is a light conduction cylinder, a concave lens is disposed beneath the convex lens of the bottom layer of the light-collecting convex lens group, the concave lens and the light-collecting convex lens group together form a convex-concave lens group, and the convex-concave lens group is coupled to the light conduction cylinder and converts the sunlight into a parallel light. The system of claim 2, characterized in that the light conduction device is the flexible fiber-optic bundle, and a front end of thereof is vertically fixed on the housing of the light collector; 
Sustav prema zahtjevu 2, naznačen time što uređaj za provođenje svjetlosti je savitljivi svjetlovodni snop, a njegov prednji kraj je okomito pričvršćen na kućište svjetlosnog kolektora; fokus konveksne leće donjeg sloja skupine konveksnih leća za skupljanje svjetlosti pada na stranu savitljivog svjetlovodnog snopa koja prima svjetlost; i stražnji kraj savitljivog svjetlovodnog snopa opremljen je sa skupinom leća stražnjeg kraja za konvergiranje i usmjeravanje svjetla na cilindar koji odašilje svjetlost.
Aqueous biofilter system (10) according to claim 11, wherein the controller (3) is arranged to adapt the dosage of the nitrogen and the phosphor source in the nutrient solution separately. 
Sustav vodenog biofiltra (10) u skladu s bilo kojim od patentnih zahtjeva 6 do 8, naznačen time, da je upravljački uređaj postavljen tako da prilagodi odvojeno doziranje izvora dušika 1 izvora fosfora u hranjivoj otopini.
1H NMR spectra were recorded at 500.13 MHz on a Bruker Avance DRX500 instrument or at 250.13 MHz on a Bruker AC 250 instrument. 
'H NMR spektri su registrirani na 500,13 MHz na instrumentu Bruker Avance DRX500 ili na 250.13 MHz na instrumentu Bruker AC 250.
The composition of aspect 1, wherein the carbohydrate is present in an amount sufficient to have stability comparable to that of a lyophilized composition comprising sucrose, 0.01 % polysorbate-20 pH 6.0, 50 mM Citrate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna da ona ima stabilnost koja odgovara onoj za liofiliziranu kompoziciju koja sadrži saharozu, 0,01 % polisorbata-20, pH 6,0, 50 mM citrata.
The method according to any one of the preceding claims, whereby the poly (ethylene glycol) has a concentration of from 5 % to 15 % by weight and the glycine has a concentration of from 3 % to 8 % by weight. The method according to any one of the preceding claims, whereby the poly (ethylene glycol) has a concentration of from 5 % to 10 % by weight and the glycine has a concentration of from 3 % to 8 % by weight. 
proizvodnja protutijela IgG-razreda u monomernom obliku primjenom otopine koja sadrži poli(etilenglikol) i sorbitol na kromatografski materijal, te time desorbiranje / eluiranje protutijela IgG-razreda u monomernom obliku iz kromatografskog materijala, pri čemu poli(etilenglikol) ima koncentraciju od 10 masenih % i sorbitol ima koncentraciju od 5 masenih % do 20 masenih %.
The method of claim 13, wherein said heterocyclic amine is selected from the group consisting of an electron withdrawing group-substituted pyridine, thiazole, pyridazine, pyrazole, triazole. 
Postupak u skladu s patentnim zahtjevom 13, naznačen time što se navedeni heterociklički amin bira iz skupine koju čine piridin supstituiran s elektron-akceptorskom skupinom, tiazol, piridazin, pirazol, triazol.
An isolated or recombinant nucleic acid comprising a polynucleotide sequence that encodes a polypeptide of claim 3, a polypeptide dimer of claim 4, a fusion protein of claim 5, or a fusion protein dimer of claim 1, 2, 6 or 7 or a monomeric fusion protein of the fusion protein dimer of claim 1 or 2, or a complementary polynucleotide sequence thereof. 
Izolirana ili rekombinantna nukleinska kiselina naznačena time da sadrži polinukleotidnu sekvencu koja kodira polipeptid prema bilo kojem od zahtjeva 1-3, dimerni polipeptid prema zahtjevu 4, fuzijski protein prema zahtjevu 5 ili zahtjevu 6, ili dimerni fuzijski protein prema zahtjevu 7 ili zahtjevu 8, ili njihovu komplementarnu polinukleotidnu sekvencu.
Preferably, the matrix includes about 10 to about 95% (by weight) polymeric material, about 0.1 to about 40% (by weight) softener, and about 0.1 to about 30% (by weight) buprenorphine. 
Preferira se da matriks uključuje približno 10 do približno 95% (mase) polimernog materijala, približno 0.1 do približno 40% (mase) omekšivača, te približno 0.1 do približno 30% (mase) buprenorfina.
After washing the column, the captured material was eluted with 35% PG. 
Nakon ispiranja kolone, uhvaćeni materijal eluiran je sa 35 % PG-om.
The collagenase for use according to Claim 1, wherein after one month of receiving at least one administration of collagenase, the patient achieves an active external rotation of greater than 15°, as compared to baseline. 
Kolagenaza za uporabu prema zahtjevu 6 ili zahtjevu 7, naznačena time da nakon jednog mjeseca primanja najmanje jednog davanja kolagenaze, pacijent postiže aktivnu vanjsku rotaciju veću od 15", u usporedbi s početnim stanjem.
is CHF2, CF3, H, F, Cl, or R1 and R2 may be taken together with their attached ring A to form a fused ring system selected from the group consisting of naphthalenyl, isoquinolinyl, and tetrahydronaphthalenyl; provided that R2 may not be H if R1 is H; 
š ii ili R'i R* mogu biti uzeti zajedno s prstenom A za koji su vezani da tvore spojeni prstenasti sustav odabran iz skupine koju čine naftalenil, izokinolinil, i tetrahidronaftalenil; pod uvjetom da R* ne može biti H ukoliko R'je H;
having an antibody-dependent cell-mediated phagocytosis (ADCP) activity; 
(b) da ima aktivnost stanično-posredovane fagocitoze zavisne od antitijela (ADCP);
Since a preserving agent of this type is often physiologically incompatible with the human body, measures have to be taken to prevent an agent of this type from being introduced into the body. 
Budući da je sredstvo za konzerviranje ove vrste često nekompatibilno s ljudskim tijelom, trebaju biti poduzete takve mjere da se spriječi da se sredstvo ovakve vrste unese u ljudsko tijelo.
EPMATHMARKEREP where r is a distance to the particular candidate point, rhs is a radius of the first distance zone, r1 and r2 are inner and outer radius of the second distance zone, respectively, for example set to r1=200 m and r2=300 m, and mean() is an average. 
<r<n) gdje je r udaljenost do određene moguće točke (411), 7,; je polumjer zone prve udaljenosti (401a), 7, i x su unutarnji odnosno vanjski polumjeri zone druge udaljenosti (401c), osobito podešeni na 7, =200 mi x» = 300 m, gdje je sred() prosjek.
r is 0 or 1 and L is O, S or NH; or their stereoisomeric and/or tautomeric forms and/or their pharmaceutically acceptable salts. 
HR P20100705 TI njel; rjedilili Lje O, S ili NH; ili njihovi stereoizomerni i/ili tautomerni oblici i/ili njihove farmaceutski prihvatljive soli.
After a white precipitate appears, 0.168 mg (2 mmol) of NaHCO3 were added. 
Kad se pojavi bijeli talog, doda se 0,168 mg (2 mmola) NaHCO:.
In a fourth aspect, this invention is compounds of the formula 
U petom aspektu, ovaj izum su spojevi formule 2
A pharmaceutical composition comprising rabies virus (RV) glycoproteins (G proteins) in a micellar particle, and a pharmaceutically acceptable carrier, diluent, or excipient. 
Postupak sukladno patentnom zahtjevu 5, naznačen time što navedeni pripravak sadrži farmaceutski prihvatljiv nosač, razrjeđivač, ili ekscipijens.
In a particularly preferred embodiment, said diphenylmethane diisocyanate comprises a mixture of diphenylmethane 4,4'-diisocyanate and diphenylmethane 2,4'-diisocyanate. 
U naročito poželjnom ostvarenju navedeni difenilmetan diizocijanat sadržava mješavinu difenilmetana 4,4'-diizocijanata i difenilmetana 2,4'-diizocijanata.
The immunogenic composition of any one of claims 1-4 wherein the at least two further bacterial saccharide conjugates comprises N. meningitidis serogroup Y capsular saccharide (MenY). 
Imunogeni pripravak u skladu s patentnim zahtjevom 3 ili 4, naznačen time što najmanje dva dodatna konjugata bakterijskih saharida sadrže saharid iz kapsule bakterije N. meningitidis seroskupina Y (MenY).
HfO2 nanoparticles or nanoparticles' aggregates for use for altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein the density of said HfO2 nanoparticles or the density of said HfO2 nanoparticles' aggregates is of at least 7 g/cm3, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
Nanočestice HfO, ili agregati nanočestica za uporabu pri mijenjanju ili uništavanju ciljnih stanica u životinje kada su spomenute stanice izložene ionizirajućim zračenjima, pri čemu je gustoća spomenutih nanočestica HfO, ili gustoća spomenutih agregata nanočestica HfO, barem 7 g/em?, i pri čemu je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između PH 6,5 1 7,5 u fiziološkoj tekućini.
Body weights are measured at the beginning (day 0) and end (day 7 or day 14) of the studies. 
Tjelesna težina mjerena je na početku (0. dan) i kraju (7. ili 14. dan) studija.